Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The study will determine if changes in expression of markers involved in the 5-FU pathways
are associated with response to treatment with the combination of lapatinib and capecitabine
independent of tumor erbB2 status.